8.36

1.46% 0.12

Aurinia Pharmaceuticals Inc (AUPH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AUPH Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$8.24

Aprire:

$8.311

Volume 24 ore:

115.39K

Relative Volume:

0.10

Capitalizzazione di mercato:

$1.16B

Reddito:

$175.51M

Utile/perdita netta:

$-78.02M

Rapporto P/E:

-15.77

EPS:

-0.53

Flusso di cassa netto:

$-34.18M

1 W Prestazione:

+0.37%

1M Prestazione:

+16.60%

6M Prestazione:

+49.56%

1 anno Prestazione:

-4.34%

Intervallo 1D:

$8.30

$8.405

Intervallo di 1 settimana:

$7.87

$8.405

Portata 52W:

$4.71

$9.74

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Nome

Aurinia Pharmaceuticals Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

250-744-2487

Indirizzo

#140, 14315 - 118 AVENUE, EDMONTON, BC

Dipendente

300

Cinguettio

@AuriniaPharma

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

AUPH's Discussions on Twitter

Confronta AUPH con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AUPH	8.36	1.16B	175.51M	-78.02M	-34.18M	-0.53
VRTX	447.51	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.90	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.12	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.20	24.49B	3.30B	-501.07M	1.03B	11.54

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-11-04	Downgrade	Oppenheimer	Outperform → Perform
2022-05-05	Ripresa	Cantor Fitzgerald	Overweight
2021-12-10	Aggiornamento	Oppenheimer	Perform → Outperform
2021-10-28	Downgrade	Oppenheimer	Outperform → Perform
2021-01-25	Reiterato	H.C. Wainwright	Buy
2020-11-03	Reiterato	H.C. Wainwright	Buy
2020-06-17	Iniziato	BTIG Research	Buy
2020-05-05	Iniziato	Cowen	Outperform
2020-01-10	Iniziato	Jefferies	Buy
2019-12-16	Reiterato	H.C. Wainwright	Buy
2018-03-16	Reiterato	Cantor Fitzgerald	Overweight
2018-02-08	Iniziato	RBC Capital Mkts	Outperform
2017-10-30	Reiterato	H.C. Wainwright	Buy
2017-05-18	Reiterato	H.C. Wainwright	Buy
2017-04-11	Iniziato	Cantor Fitzgerald	Overweight
2017-03-22	Reiterato	FBR & Co.	Outperform
2016-12-30	Reiterato	H.C. Wainwright	Buy
2016-08-17	Reiterato	H.C. Wainwright	Buy
2016-06-30	Iniziato	H.C. Wainwright	Buy
2015-05-08	Iniziato	MLV & Co	Buy

Mostra tutto

Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie

Nov 18, 2024

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Business Wire

Nov 18, 2024

Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace

Nov 18, 2024

Nov 17, 2024

(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 17, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat

Nov 17, 2024

Nov 15, 2024

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise

Nov 15, 2024

ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Aurinia to Participate in Jefferies London Healthcare Conference - sharewise

Nov 14, 2024

Aurinia Pharmaceuticals Engages at London Conference - TipRanks

Nov 14, 2024

Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock - Investing.com India

Nov 14, 2024

Nov 12, 2024

Aurinia Pharmaceuticals director sells shares valued at $38,415 - Investing.com India

Nov 12, 2024

Aurinia Pharmaceuticals director sells shares valued at $38,415 By Investing.com - Investing.com Canada

Nov 12, 2024

Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock By Investing.com - Investing.com UK

Nov 12, 2024

Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com - Defense World

Nov 12, 2024

Aurinia Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH) - Seeking Alpha

Nov 08, 2024

Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - Pharmaceutical Technology

Nov 08, 2024

Nov 07, 2024

Earnings call: Aurinia Pharmaceuticals announced a 24% increase in total net revenue - Investing.com

Nov 07, 2024